Fate Therapeutics Q3 rev $3.1M, cash $330.5M; FT819/FT522/FT825 clinical progress

FATE THERAPEUTICS INC

2024-Q3 EPS reported -$1.19 revenue$11,771,000

Q3 revenue of $3.1M from Ono collaboration; total op expense $55.5M incl $11.8M stock comp.
Cash, equivalents & investments $330.5M; projected operating runway through end of 2026.
FT819 Phase 1 SLE: 3 patients dosed with fludarabine-free conditioning; no DLTs/CRS/ICANS/GvHD; data at ACR and ASH.
FT522 IND allowed for B cell-mediated autoimmune basket study; initial BCL clinical data at ACR Convergence.
FT825/ONO-8250 initial solid tumor data: safety profile favorable, CAR T expansion with activated phenotype at 100M dose.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.